<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788294</url>
  </required_header>
  <id_info>
    <org_study_id>A4091013</org_study_id>
    <nct_id>NCT00788294</nct_id>
  </id_info>
  <brief_title>Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously</brief_title>
  <official_title>Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that subcutaneous administration of tanezumab results in
      lower drug exposure compared to intravenous administration of tanezumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subcutaneous bioavailability</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site reactions</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nerve growth factor levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>10 mg IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>19 mg SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>Drug solution given intravenously only once at dose of 10 mg</description>
    <arm_group_label>10 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>Drug solution given subcutaneously only once at dose of 5 mg.</description>
    <arm_group_label>5 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>Drug solution given subcutaneously only once at dose of 10 mg.</description>
    <arm_group_label>10 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>Drug solution given subcutaneously only once at dose of 19 mg.</description>
    <arm_group_label>19 mg SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy

          -  BMI of 18-30 kg/m2

          -  more than 50 kg bodyweight.

        Exclusion Criteria:

          -  Pregnant

          -  exposure to biologic type drugs within the last 3 months

          -  history of allergic or anaphylactic reaction to a biologic drug

          -  use of tobacco- or nicotine containing products that is more than what is in 5
             cigarettes per day

          -  excessive alcohol use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091013&amp;StudyName=Measure%20Exposure%20Of%20Tanezumab%20In%20Healthy%20Volunteers%20When%20Administering%20The%20Drug%20Subcutaneously</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Pharmacokinetics tanezumab subcutaneous bioavailability intravenous Japanese subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

